Treatment Strategies for Cardiomyopathy in Children
Published: June 08, 2023
- Treatment strategies for cardiomyopathy in children should be designed to develop personalized therapy for each patient through an effort to identify a) the specific cardiac pathophysiology(ies) and, if possible, b) the root cause or specific etiology that exist in each patient.
- Pediatric cardiomyopathy should be recognized as a problem that may be diagnosed in a variety of clinical milieus: a) patients at risk for cardiomyopathy with a negative phenotype; b) patients with a positive cardiomyopathy phenotype but asymptomatic; c) symptomatic cardiomyopathy, and d) end-stage disease. Therapeutic strategies should be tailored to the specific clinical milieu in each patient.
- Heart failure in children differs in important ways from heart failure in adults. Recent studies have found distinct pathologic, transcriptomic, and proteomic profiles in pediatric heart failure compares to adults. In addition, children lack many of the comorbid conditions present in adults. These differences may influence the efficacy of adult heart failure treatments when applied in pediatric patients.
Supporting Materials
Recommended Reading
- Guideline for the Management of Heart Failure: Executive Summary
- Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary
- Cardiomyopathy in Children: Classification and Diagnosis
- Update on Pharmacological Heart Failure Therapies in Children
- Age-Related Differences in Phosphodiesterase Activity and Effects of Chronic Phosphodiesterase Inhibition in Idiopathic Dilated Cardiomyopathy